05th week of 2013 patent applcation highlights part 40 |
Patent application number | Title | Published |
20130028917 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF - Conjugates and compounds for making conjugates which are PBD molecules linked via the N10 position are disclosed, along with the use of the conjugates for treating proliferative diseases, including cancer. | 2013-01-31 |
20130028918 | INSULIN CONJUGATE USING AN IMMUNOGLOBULIN FRAGMENT - The present invention relates to an insulin conjugate having improved in vivo duration and stability, which is prepared by covalently linking insulin with an immunoglobulin Fc region via a non-peptidyl polymer, a long-acting formulation comprising the same, and a preparation method thereof. The insulin conjugate of the present invention maintains in vivo activity of the peptide at a relatively high level and remarkably increases the serum half-life thereof, thereby greatly improving drug compliance upon insulin treatment. | 2013-01-31 |
20130028919 | TARGETED PYRROLOBENZODIAZAPINE CONJUGATES - Provided are Conjugate comprising PBDs conjugated to a targeting agent and methods of using such PBDs. | 2013-01-31 |
20130028920 | STABILIZED ANTIBODY PREPARATIONS AND USES THEREOF - The present invention is directed to stabilized intact antibody formulations, related methods and uses thereof. In particular, the invention relates to a method of stabilizing an intact antibody in a liquid carrier. | 2013-01-31 |
20130028921 | COMPOSITION COMPRISING COUMESTROL OR A BEAN EXTRACT CONTAINING COUMESTROL - The present invention relates to a composition which comprises as an active ingredient coumestrol or a bean extract containing coumestrol, whereby adipocyte differentiation is inhibited, the immune system of the body is improved, toxic substances are purged, and neurodegenerative disorders are prevented or improved. | 2013-01-31 |
20130028922 | CITRULLINE PEPTIDES DERIVED FROM FIBRIN AND RECOGNIZED BY RHEUMATOID ARTHRITIS SPECIFIC AUTOANTIBODIES, AND THE USE THEREOF - The invention relates to novel citrulline peptides derived from fibrin α and β chains which are recognizable by specific citrulline antiprotein autoantibodies (AAPC) of a rheumatoid arthritis (PR) and to the use thereof for detecting the presence of said specific PR AAPC in a biological sample. | 2013-01-31 |
20130028923 | KDR PEPTIDES AND VACCINES COMPRISING THE SAME - The present invention provides nonapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:2, 3, 5, 8, 11, or 12; nonapeptides or decapeptides selected from peptides comprising the amino acid sequence of SEQ ID NO:29, 30, 33, 34, 40, or 46; and peptides with cytotoxic T cell inducibility, in which one, two, or several amino acids are substituted or added to the above-mentioned amino acid sequences, as well as pharmaceuticals for treating or preventing tumors, where the pharmaceuticals comprise these peptides. The peptides of this invention can be used as vaccines. | 2013-01-31 |
20130028924 | CONSTRUCTS FOR ENHANCING IMMUNE RESPONSES - Chimeric protein constructs including a herpesvirus glycoprotein D (gD) and a heterologous polypeptide that interact with herpes virus entry mediator (HVEM) and enhance and enhance an immune response against the heterologous polypeptide and methods for their use are provided. | 2013-01-31 |
20130028925 | HERPES SIMPLEX VIRUS COMBINED SUBUNIT VACCINES AND METHODS OF USE THEREOF - This invention provides immunogenic compositions comprising two or three recombinant Herpes Simplex Virus (HSV) proteins selected from a gD protein, a gC protein and a gE protein; and methods of impeding immune evasion by HSV, inducing an anti-HSV immune response, and treating, suppressing, inhibiting, and/or reducing an incidence of an HSV infection or a symptom or manifestation thereof, comprising administration of a vaccine of the present invention. | 2013-01-31 |
20130028926 | BIOSYNTHETIC SYSTEM THAT PRODUCES IMMUNOGENIC POLYSACCHARIDES IN PROKARYOTIC CELLS - The invention is directed to bioconjugate vaccines comprising N-glycosylated proteins. Further, the present invention is directed to a recombinant prokaryotic biosynthetic system comprising nucleic acids encoding an epimerase that synthesizes an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus. The invention is further directed to N-glycosylated proteins containing an oligo- or polysaccharide having N-acetylgalactosamine at the reducing terminus and an expression system and methods for producing such N-glycosylated proteins. | 2013-01-31 |
20130028927 | METHOD OF DIAGNOSING AND TREATING MELIOIDOSIS - Non-invasive methods are provided herein for the diagnosis of melioidosis with specific antibodies capable of detecting molecules associated with melioidosis in a biological fluid, such as urine or serum. These molecules can be identified using proteomic methods, including but not limited to antibody based methods, such as an enzyme-linked immunosorbant assay (ELISA), a radioimmunoassay (RIA), or a lateral flow immunoassay. Methods of inducing an immune response to melioidosis are also disclosed. The methods include the use of the immunogenic melioidosis polypeptides, nucleic acids encoding these polypeptides, and/or viral vectors encoding an immunogenic melioidosis polypeptide, alone or in conjunction with other agents, such as traditional melioidosis therapies. Also disclosed are methods for treating a subject having melioidosis. These methods include inducing an immune response to melioidosis and/or using an inhibitory nucleic acid, such as a siRNA or antisense molecule, to decrease a melioidosis associated molecule expression in order to treat melioidosis. | 2013-01-31 |
20130028928 | Methods to increase antigenicity of membrane bound polypeptides produced in plants - Increased antigenicity of a membrane bound polypeptide produced from plants is provided by reducing fat content of the plant, plant part, or plant tissue producing the polypeptide. Methods and means of producing such plant material are provided. Methods to produce a protective immune response in animals are provided by administering to the animal the plant, plant part of plant tissue which has reduced fat content and which comprises the polypeptide or by administering to the animal an extracted polypeptide produced from such a plant. | 2013-01-31 |
20130028929 | FUNCTIONAL BEVERAGE COMPOSITION COMPRISING CHLORELLA AND DEEP SEA WATER - The present invention relates to a functional beverage composition comprising | 2013-01-31 |
20130028930 | Albumin Derivatives and Variants - The application discloses albumin derivatives comprising or consisting of domain III and at least one further domain wherein the derivative or variant is not a naturally occurring albumin derivative or variant. The derivatives may be used in conjugates and fusion polypeptides. | 2013-01-31 |
20130028931 | NOVEL PRRS VIRUS INDUCING TYPE I INTERFERON IN SUSCEPTIBLE CELLS - The present invention relates to the field of attenuated live viruses useful as vaccine or medicament for preventing or treating Porcine Reproductive and Respiratory Syndrome (PRRS) in swine, and is based on the surprising finding of a PRRS virus which is able to induce the interferon type I response of a cell infected by said virus. In one embodiment, the PRRS virus according to the invention is a PRRS virus mutant comprising, in comparison with the genome of a wild type strain, a mutation in the gene encoding the non structural protein 1 (nsp1) of said virus. | 2013-01-31 |
20130028932 | COMPOSITIONS COMPRISING POLYGLUTAMIC ACID NANOPARTICLES AND POLYPEPTIDES SUCH AS CD40 AGONISTS - The present invention provides pharmaceutical compositions comprising an immunostimulatory polypeptide and polyglutamic acid (PGA) nanoparticles, formulated in a pharmaceutically acceptable diluent, carrier or excipient. Such compositions have utility in stimulating the immune system in subjects, with the components capable of interacting synergistically. The invention further provides uses of the compositions of the invention, for example in the treatment of cancer, and kit and components for use in the same. | 2013-01-31 |
20130028933 | METHODS FOR STABILIZING INFLUENZA ANTIGEN ENVELOPED VIRUS-BASED VIRUS-LIKE PARTICLE SOLUTIONS - Methods of stabilizing solutions with enveloped vims-based virus-like particles containing an influenza antigen and such stabilized solutions are described. | 2013-01-31 |
20130028934 | Stabilizer and Vaccine Composition Comprising One or More Live Attenuated Flaviviruses - The present invention relates to stabilizers for compositions, including immunogenic compositions, such as vaccine compositions, comprising one or more live attenuated flaviviruses, to bulk vaccine compositions stabilized with these stabilizers, particularly dry vaccine compositions prepared from these bulk vaccine compositions, and to methods for stabilizing one or more live attenuated flaviviruses. | 2013-01-31 |
20130028935 | COMPOSITION CONTAINING HCMV PARTICLES - The present invention is related to a composition comprising an agent selected from the group comprising HCMV virions, HCMV dense bodies and HCMV NIEP, whereby the composition is capable of elucidating an immune response while the virions, the NIEP and/or the dense bodies being non-fusiogenic. | 2013-01-31 |
20130028936 | TLR 4 AND 9 RECEPTORS AGONISTS FOR PREVENTING SEPTIC COMPLICATIONS OF POST-TRAUMATIC IMMUNODEPRESSION IN PATIENTS HOSPITALIZED FOR SEVERE TRAUMATIC INJURIES - The present invention concerns a pharmaceutical composition comprising at least one agonist of at least one Toll Like receptor (TLR) chosen from TLR 4 and 9, for use in the prophylactic treatment of septic complications of post-traumatic systemic immunodepression in a patient who has suffered one or more severe traumatic injuries and is hospitalized in particular in an intensive care unit. Preferably, said TLR 4 agonist is monophosphoryl lipid A (MPLA) or deacylated 3-O-monophosphoryl lipid A (3D-MPLA) and said TLR 9 agonist is a CpG oligodeoxynucleotide (CpG ODN). | 2013-01-31 |
20130028937 | CO-CRYSTALS OF VENLAFAXINE AND CELECOXIB - The present invention relates to a co-crystal of celecoxib and venlafaxine, processes for preparation of the same and its use as medicaments or in pharmaceutical formulations, more particularly for the treatment of pain, including chronic pain; or of depression in patients which suffer from chronic pain and/or chronic inflammation or in patients with a chronic musculo-skeletal inflammatory illness, with the inflammatory illness preferably being selected from osteoarthritis or rheumatoid arthritis. | 2013-01-31 |
20130028938 | SOLID PHARMACEUTICAL DOSAGE FORM - The present invention relates to a solid pharmaceutical dosage form comprising ticagrelor as pharmaceutically active ingredient, to certain particles of ticagrelor and to processes of preparing the same. | 2013-01-31 |
20130028939 | CHIMERIC HUMAN BETA DEFENSINS - The invention relates to a nucleic acid molecule selected from the group comprising a) a nucleic acid molecule having one of the nucleotide sequences presented in SEQ ID:NO 4 to SEQ ID:NO 8, b) a nucleic acid molecule that codes for a peptide having one of the amino acid sequences presented in SEQ ID:NO 12 to SEQ ID:NO 16, c) a nucleic acid molecule, the complementary strand of which hybridizes to a nucleic acid molecule according to a) or b) and which codes for a peptide having antimicrobial activity, and d) a nucleic acid molecule, the nucleotide sequence of which deviates from the nucleotide sequence of a nucleic acid molecule according to c) because of the degenerated genetic code. | 2013-01-31 |
20130028940 | CASPOFUNGIN FORMULATIONS - The present invention relates to pharmaceutical compositions comprising a pharmaceutically acceptable salt of caspofungin as active ingredient being useful for the prevention and/or treatment of fungal infections. Said compositions additionally comprise specific bulking agents and small amounts or no amounts of an additional pH modifier and may be in a liquid or solid form, e.g. may be lyophilized compositions. Said compositions show good stability and reduced amounts of sub-visible particulate matter formed in solutions which are reconstituted from the lyophilized product. | 2013-01-31 |
20130028941 | SYNTHETIC NANOCARRIERS THAT GENERATE HUMORAL AND CYTOTOXIC T LYMPHOCYTE (CTL) IMMUNE RESPONSES - Disclosed are methods for generating humoral and cytotoxic T lymphocyte (CTL) immune responses in a subject and related compositions. | 2013-01-31 |
20130028942 | AEROSOLIZED NITRITE AND NITRIC OXIDE-DONATING COMPOUNDS AND USES THEREOF - Disclosed herein are formulations of nitrite, nitrite salt, or nitrite- or nitric oxide-producing compounds suitable for aerosolization and use of such formulations for aerosol administration of nitrite, nitrite salt, or nitrite- or nitric oxide-donating compounds for the treatment of pulmonary arterial hypertension, intra-nasal or pulmonary bacterial infections, or to treat or prevent ischemic reperfusion injury of the heart, brain and organs involved in transplantation. In particular, inhaled nitrite, nitrite salt, or nitrite- or nitric oxide-donating compound specifically formulated and delivered to the respiratory tract for the indications is described. Compositions include all formulations, kits, and device combinations described herein. Methods include inhalation procedures and manufacturing processes for production and use of the compositions described. | 2013-01-31 |
20130028943 | MELATONIN TABLET AND METHODS OF PREPARATION AND USE - The present invention provides a pharmaceutical composition for sublingual or buccal administration of actives with low to poor aqueous solubility, e.g. the indole hormone melatonin, which contains a solution of the active in a pharmaceutically acceptable solvent adsorbed or absorbed onto particles of a pharmaceutically acceptable carrier and methods of preparing and using the pharmaceutical composition. | 2013-01-31 |
20130028944 | NOVEL METHODS FOR TARGETING CANCER STEM CELLS - The invention provides naphthofuran compounds, polymorphs of naphthofuran compounds, naphthofuran compounds in particle form, purified compositions that contain one or more naphthofuran compounds, purified compositions that contain one or more naphthofuran compounds in particle form, methods of producing these naphthofuran compounds, polymorphs, purified compositions and/or particle forms, and methods of using these naphthofuran compounds, polymorphs, purified compositions and/or particle forms to treat subjects in need thereof. | 2013-01-31 |
20130028945 | NOVEL COMPOSITION FOR TREATMENT OF ESSENTIAL THROMBOCYTHEMIA - The present invention relates to a novel pharmaceutical composition free of gastric coating comprising anagrelide hydrochloride in combination with a non-pH dependent polymer and a pharmaceutically acceptable watersoluble acid and its use for the treatment of essential thrombocythemia. | 2013-01-31 |
20130028946 | RELATING TO ANTIVIRAL COMPOSITIONS - The present invention provides a composition and an antiviral drug preparation, each comprising at least one water-insoluble antiviral drug and at least one water-soluble carrier material, wherein the water-insoluble antiviral drug is dispersed through the water-soluble carrier material in nano-disperse form. The present invention further provides processes for preparing the compositions and drug preparations, and also aqueous nano-dispersions obtained by combining water and the compositions. | 2013-01-31 |
20130028947 | PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION - A topical pharmaceutical composition which has a hydrophilic outer phase, at least one pharmaceutical active ingredient and at least one carrier substance. The carrier substance has at least two lamellar double membrane layers arranged one over another in the manner of a sandwich, wherein between adjacent double membrane layers, aligned parallel to each other, a layer of an inner phase is arranged. The active ingredient is distributed in the double membrane layer and in the layer of the inner phase such that the layer of the inner phase contains the active ingredient in a concentration range between 2% by weight and 98% by weight and the double membrane layer contains the active ingredient in a concentration between 98% by weight and 2% by weight, and the outer phase has no or almost no active ingredient. | 2013-01-31 |
20130028948 | COMPOSITE PARTICLES AND METHOD FOR PRODUCTION THEREOF - Disclosed are titanium dioxide-containing composite particles which can maintain whiteness of natural titanium dioxide even after calcination step, and can provide titanium dioxide-containing composite particles having excellent weather resistance. In each of the composite particles, at least one oxide layer containing silicon oxide and zirconium oxide is provided as coating components of titanium dioxide. That is, provided are composite particles including a base that contains titanium dioxide and at least one oxide layer that contains silicon oxide and zirconium oxide provided on the base, and a method of producing the composite particles. | 2013-01-31 |
20130028949 | COSMETIC SPONGE AND METHOD FOR PROVIDING A COSMETIC SPONGE - This invention relates to a cosmetic sponge and a method of providing a cosmetic sponge incorporating a non-denatured collagen and other additives for skin care, cleaning, and cosmetic application. | 2013-01-31 |
20130028950 | Vesicle-Containing Composition - The present invention provides a vesicle-containing composition having an excellent stability in the presence of water-soluble medicinal agent. A vesicle-containing composition of the present invention is characterized by comprising: | 2013-01-31 |
20130028951 | Polymer-Liposome Nanocomposite Composition for Percutaneous Absorption, and Method for Preparing Same - Provided are a polymer/liposome nanocomposite composition comprising lipids and poly(amino acids), and a method for preparing same. The polymer/liposome nanocomposite composition has excellent formation stability with respect to surfactants and salts, and can be used in various ways as a drug delivery system in the fields of medicine and cosmetics. | 2013-01-31 |
20130028952 | FILLER PIGMENTS - Filler pigments based on platelet-shaped substrates, which are coated with barium sulfate and at least two metal oxides and/or metal hydroxides are highly suitable as filler pigments especially for cosmetic formulations. | 2013-01-31 |
20130028953 | Transdermal Delivery Systems for Sufentanil - Transdermal delivery systems for administering sufentanil through the skin are provided. The systems contain a sufficient amount of sufentanil to induce and maintain a constant state of analgesia when applied to a subject. The systems are characterized as having one or more features including a high degree of dosage form rate control over flux of sufentanil from the system, a high net flux of sufentanil from the system through the skin, lack of a permeation enhancer, an adhesive member demonstrating superior shear time, a low coefficient of variation in the net flux of sufentanil from the system, a high delivery efficiency, and a substantially constant steady state net flux of sufentanil from the system. Methods of using the transdermal delivery systems to administer a sufficient amount of sufentanil to induce and maintain analgesia for extended periods when applied to a subject are also provided. | 2013-01-31 |
20130028954 | HEMOSTATIC DRESSING - The present invention relates to a hemostatic dressing which comprises a plurality of layers that contain resorbable materials and/or coagulation proteins. In particular, the invention includes dressings in which a layer of thrombin is sandwiched between a first and second layer of fibrinogen and wherein the layer of thrombin is not coextensive with the first and/or second layer of fibrinogen. The hemostatic dressings are useful for the treatment of wounded tissue. | 2013-01-31 |
20130028955 | SUSTAINED RELEASE ORAL MATRIX AND METHODS OF MAKING THEREOF - A solid dosage form suitable for forming a tablet for the containment and delivery of medicament is provided wherein the matrix forming material is a pressure sensitive adhesive, present in the amount from about 0.1 to about 40 weight %, based on the total weight of the composition. The dosage form is comprised of the medicament and a water-insoluble polymer silicone pressure sensitive adhesive and allows release of the medicament in a controlled fashion depending on simple parameters such as weight percent of the polymer silicone adhesive. A sustained release dosage form is provided for delivery of medicament wherein the release rate of medicament does not depend on the dissolution medium of the pH. Another aspect of invention is formation of solid tablets of poorly compressible material and the method for making the solid composition. The dosage form for this invention s particularly suitable for oral dosage forms. | 2013-01-31 |
20130028956 | METHOD FOR PREVENTING OR TREATING MEMORY IMPAIRMENT AND PHARMACEUTICAL COMPOSITIONS USEFUL THEREFORE - In a first aspect, the present invention relates to a method for prevention or treating memory impairment and/or a neurodegenerative condition, disorder or disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound targeting a miRNA or any precursor, or targeting the activity of said miRNA or any precursor thereof. In particular, the present invention relates to a method wherein the targeted miRNA is miR-34. Moreover, the present invention relates to a method for improving memory functionality in a subject suffering from memory loss, said method comprises the reduction or reducing the level of miR-34 levels or precursor molecule levels in brain tissue of said subject administering to the subject a therapeutically effective amount of a compound targeting miR-34 or any precursor thereof. | 2013-01-31 |
20130028957 | PHARMACEUTICAL COMPOSITION FOR TREATING CANCER - The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent. | 2013-01-31 |
20130028958 | BETA-CARBOLINES FOR USE IN THE TREATMENT OF HEARING LOSS AND VERTIGO - The present invention is directed at β-carbolines, preferred 9-alkyl-β-carbolines ( | 2013-01-31 |
20130028959 | Liposomes for Preventing the Spread of HIV - Formulations for preventing the sexual transmission of the HIV virus are provided. In one embodiment, the formulations contain un-conjugated liposomes whose physicochemical properties allow binding to the HIV virus. The liposomes are made up of natural or synthetic lipids, alone or in combination. Preferably, the liposomes are made entirely of cardiolipin. In other embodiments the liposomes are modified to contain Hgands which bind HIV. The method for preventing the sexual transmission of the HIV virus includes self-administration of a formulation containing an effective amount of liposomes which bind to the HIV virus to the surface of a mucosal membrane prior to intercourse. | 2013-01-31 |
20130028960 | LIPID-BASED COMPOSITIONS OF ANTIINFECTIVES FOR TREATING PULMONARY INFECTIONS AND METHODS OF USE THEREOF - A system for treating or providing prophylaxus against a pulmonary infection is disclosed comprising: a) a pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition, and b) an inhalation delivery device. A method for providing prophylaxis against a pulmonary infection in a patient and a method of reducing the loss of antiinfective encapsulated in a lipid-based composition upon nebulization comprising administering an aerosolized pharmaceutical formulation comprising a mixture of free antiinfective and antiinfective encapsulated in a lipid-based composition is also disclosed. | 2013-01-31 |
20130028961 | PHARMACEUTICAL COMPOSITIONS, COMPRISING A COMBINATION OF SELECT CARRIERS, VITAMINS, TANNINS AND FLAVONOIDS AS ANTIGEN-SPECIFIC IMMUNO-MODULATORS - The present invention provides adjuvant compositions that are capable of modulating the immune response in a subject, including enhancing or suppressing the immune response. These adjuvant compositions may also be used to enhance or suppress the immunogenicity of antigens by enhancing or suppressing antigen-presentation activity, enhancing or suppressing innate immune responses through activation or suppression of, e.g., natural killer cells, and/or direct activation of subsets of B and/or T cells. Also provided are methods of making the adjuvant compositions as well as methods of using the adjuvant compositions. In certain embodiments, the compositions comprise combinations of the following: a pharmaceutically acceptable carrier, a flavonoid, a tannin and a vitamin. The compositions may further comprise an antigen. | 2013-01-31 |
20130028962 | Triggered Cargo Release from Nanoparticle Stabilized Liposomes - Control of the fusion activity of liposomes by adsorbing biocompatible nanoparticles to the outer surface of phospholipid liposomes is disclosed. The biocompatible nanoparticles effectively prevent liposomes from fusing with one another. Release of cargo from the liposome is accomplished via trigger mechanisms that include pH triggers, pore forming toxing triggers and photosensitive triggers. Dermal drug delivery to treat a variety of skin diseases such as acne vulgaris and staph infections is contemplated. | 2013-01-31 |
20130028963 | Forming an Artificial Cell with controlled membrane composition, asymmetry, and contents - The present invention provides a vesicle having a unilamellar bilayer including a lipid and a second bilayer component selected from a membrane protein or a functionalized lipid. The vesicle also includes a component encapsulated by the unilamellar bilayer, wherein the encapsulated component includes a protein, a peptide, an enzyme, an oligonucleotide, or a polynucleotide. Also included are methods of making the vesicles of the present invention. | 2013-01-31 |
20130028964 | NOVEL RNAi THERAPEUTIC FOR TREATMENT OF HEPATITIS C INFECTION - Small interfering RNAs (siRNAs) or small hairpin RNA (shRNAs) and compositions comprising same are provided that target human cyclophilin A (CyPA) to inhibit Hepatitis C (HCV) infection. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A (CyPA) cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNA and shRNAs may be formulated as naked compositions or pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are also provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing inhibiting, preventing, etc., HCV infection using such siRNA and shRNAs and compositions comprising same are also provided. | 2013-01-31 |
20130028965 | NOVEL RNAi THERAPEUTIC FOR TREATMENT OF HEPATITIS C INFECTION - Small interfering RNAs (siRNAs) or small hairpin RNA (shRNAs) and compositions comprising same are provided that specifically target human cyclophilin A (CyPA) to effectively inhibit Hepatitis C (HCV) infection in a cell. Such siRNA and shRNAs may have a length of from about 19 to about 29 contiguous nucleotides corresponding to a specific region of human cyclophilin A (CyPA) cDNA of from about nucleotide 155 to about nucleotide 183 having particular potency against CyPA and HCV. Such siRNA and shRNAs may be formulated as naked compositions or as pharmaceutical compositions. DNA polynucleotides, plasmids, and viral or non-viral vectors are also provided that encode siRNA or shRNA molecules, which may be delivered directly to cells or in combination with known delivery agents, such as lipids, polymers, encapsulated lipid particles, such as liposomes. Methods for treating, managing inhibiting, preventing, etc., HCV infection using such siRNA and shRNAs and compositions comprising same are also provided. | 2013-01-31 |
20130028966 | Broad Spectrum Antiviral and Antiparasitic Agents - The invention provides compounds represented by the formulae: (I) and (II) where the compounds are useful in treating, for example, viral and/or parasitic infections. Also provided are pharmaceutical compositions comprising the compounds and methods of treatment using the compounds. | 2013-01-31 |
20130028967 | THERAPEUTIC AGENT FOR PULMONARY FIBROSIS - Disclosed are: a substance transfer carrier to an extracellular matrix-producing cell in the lung, which comprises a retinoid; a therapeutic agent for pulmonary fibrosis, which utilized the carrier; and a preparation kit of the therapeutic agent. | 2013-01-31 |
20130028968 | COMPOSITIONS AND METHODS TO RELIEVE CHRONIC DISEASES SYMPTOMS - Compounds having unique properties are prepared from the herbal compositions described herein and comprise extracts derived from plants and fungi of the genera | 2013-01-31 |
20130028969 | METHOD FOR STABLE AND CONTROLLED DELIVERY OF (-)-HYDROXYCITRIC ACID - The present invention provides stable encapsulated (−)-hydroxycitric acid (“HCA”)-containing compositions and methods of making the same. A method is provided by which the hygroscopic salts of HCA in their relatively pure and active forms, including especially the potassium salt, but also including the sodium salt, are rendered non-hygroscopic and stable (that is, not prone to lactonization, not readily subject to attachment to ligands which inhibit absorption or lead to excretion, and so forth) such that these HCA salts might be included in dry delivery formats, liquid delivery and in controlled-release vehicles. The nonhygroscopic salts of HCA and its derivatives likewise may be protected against acid degradation, lactonization and undesirable ligand binding when exposed to acidic environments or other challenging conditions. The method taught herein can be employed to reduce the polar/ionic qualities of HCA salts and derivatives when presented to the intestinal lumen to provide advantages in absorption. | 2013-01-31 |
20130028970 | Tamper-resistant tablet providing immediate drug release - The invention relates to a tamper-resistant tablet comprising
| 2013-01-31 |
20130028971 | Pharmaceutical Compositions Comprising Rifaximin, Processes For Their Preparation And Their Use In The Treatment Of Vaginal Infections - The invention relates generally to pharmaceutical compositions comprising rifaximin effective at treating vaginal infections, and in particular bacterial vaginosis. The pharmaceutical compositions comprising rifaximin granules are characterized in that they release rifaximin in the vagina in a controlled way. The present invention also relates to processes for preparation of the rifaximin pharmaceutical compositions and their use in the treatment of vaginal infections. Effective dosages and courses of treatment useful and effective at recovering from the disease and preventing any possible relapse are also provided. | 2013-01-31 |
20130028972 | Tamper-resistant tablet providing immediate drug release - The invention relates to a tamper-resistant tablet comprising
| 2013-01-31 |
20130028973 | PARTICULATE COMPRISING A CALCIUM-CONTAINING COMPOUND AND A SUGAR ALCOHOL - The present invention relates to a particulate material and a solid dosage form notably tablets comprising a regularly shaped calcium-containing compound such as a calcium salt as a therapeutically and/or prophylactically active substance and a pharmaceutically acceptable sugar alcohol such as, e.g., sorbitol and/or isomalt that has a micro structure as evidenced by SEM. The invention also relates to a process for the preparation of the particulate material and solid dosage form. The process involves agglomeration of the calcium-containing compound and the pharmaceutically acceptable sugar alcohol by means of roller compaction. The particulate material obtained by roller compaction is suitable for use in the further processing of the particulate material into e.g. tablets such as chewing tablets. | 2013-01-31 |
20130028974 | PHARMACEUTICAL FORMULATION IN THE FORM OF BILAYERED TABLETS COMPRISING HMG-COA REDUCTASE INHIBITOR AND IRBESARTAN - Provided is a pharmaceutical formulation in the form of a bilayered tablet consisting of a first layer containing irbesartan or a pharmaceutically acceptable salt thereof and a second layer containing an HMG-CoA reductase inhibitor and a basic additive, which can improve the dissolution rate and stability of irbesartan and an HMG-CoA reductase inhibitor to enhance the bioavailability of the drug compared to conventional complex formulations and to minimize the generation of the related compounds, thereby being effectively used as a stable and superior therapeutic agent for hypertension and hypercholesterolemia. | 2013-01-31 |
20130028975 | HEMOSTATIC SPONGE - The present invention provides a hemostatic porous composite sponge comprising i) a matrix of a biomaterial and ii) one hydrophilic polymeric component comprising reactive groups wherein i) and ii) are associated with each other so that the reactivity of the polymeric component is retained, wherein associated means that—said polymeric component is coated onto a surface of said matrix of a biomaterial, or—said matrix is impregnated with said polymeric material, or—both. | 2013-01-31 |
20130028976 | SPRAY-DRIED CRYSTALLINE ACTIVE INGREDIENT - A process for preparing a spray-dried product for improving the rate of dissolution of the active ingredient. The process includes mixing a crystalline active ingredient, which has a dissolution rate in unstirred water at 25° C. of greater than 15 minutes at a concentration of 14 ppm of the active ingredient, with a starch derivative, a second carrier material, and optionally, xanthan gum, to form a suspension, dispersion or solution of the active ingredient; homogenizing the mixture at a pressure of at least 4000 psig (2.758×10 | 2013-01-31 |
20130028977 | PHARMACEUTICAL POWDER COMPOSITION FOR INHALATION - The present invention relates to a pharmaceutical powder composition for inhalation comprising an active ingredient and a pharmaceutically acceptable carrier, process for preparing such composition, and its use for the treatment of respiratory disorder in a subject. | 2013-01-31 |
20130028978 | COMPOSITIONS AND METHODS FOR WOUND TREATMENT - Provided herein are compositions, methods, systems, and kits for wound healing. As shown herein, CCN2/CTGF stimulated mesenchymal progenitor cells can form αSMA | 2013-01-31 |
20130028979 | Stretch Marks Cream - A topical composition and method for making, including the steps of placing cow's tallow in water and heating; allowing the heating tallow to float to the top of the water; filtering the floating portion of the tallow from the rest of the water; placing the floating portion of tallow obtained from the filtering into a container containing the bee's wax, camphor, and alum powder; maintaining the mixture at low heat; allowing all four ingredients to have blended; cooling the mixture from the low heat; and refrigerating the mixture. The temperature of heating the cow's tallow is sufficient to render the four ingredients blendable. | 2013-01-31 |
20130028980 | CELL-POLYMER FIBER COMPOSITIONS AND USES THEREOF - The present invention relates to compositions comprising complexes of human cells and polymer fibers and methods of their use for therapeutic purposes. Methods of making such compositions are also provided. The present invention encompasses compositions comprising poly-β-1→4-N-acetylglucosamine polymers and stored platelets and their use for promoting wound healing and achieving hemostasis. | 2013-01-31 |
20130028981 | METHODS FOR TISSUE DECELLULARIZATION - A method for producing sterile, decellurized bioprosthetic tissue comprising: (a) contacting a human tissue with a hypotonic solution to produce a lysed tissue, (b) contacting the lysed tissue with a first surfactant to produce a surfactant-treated tissue, (c) contacting the surfactant-treated tissue with a nuclease enzyme solution to produce an enzyme-treated tissue, (d) contacting the enzyme-treated tissue with a cleaning solution comprising a second surfactant, a chaotropic agent or a mixture thereof to produce a decellurized tissue and (e) contacting the decellurized tissue with a bioburden reducing agent to produce the final bioprosthetic tissue. Kits to be used in conjunction with said method, as well as, the bioprosthetic tissue produced via said method are also provided. | 2013-01-31 |
20130028983 | Indicator for Oxygen Generation - There is provided on-demand, oxygen generating topical compositions having a built-in indicator specifically to indicate a color change upon the complete mixing of the oxygen precursor and catalyst. The first part of the composition contains a carrier and manganese dioxide (MnO2) nanoparticles. The second part of the composition comprises the oxygen precursor; hydrogen peroxide. When the two parts, one with manganese dioxide nanoparticles and exhibiting a characteristic color, (e.g. yellow brown) and the second part with hydrogen peroxide are mixed together, the color imparted by the manganese dioxide nanoparticles essentially disappears and the final composition (enriched with oxygen) either appears colorless or takes on the original color of the catalyst. Thus, the manganese dioxide catalyst nanoparticles themselves serve as the colorimetric indicator of peroxide decomposition to oxygen, precluding the need for an external colorant. Manganese dioxide particles that are not nanoparticles fail to exhibit this color changing phenomenon. | 2013-01-31 |
20130028984 | NATURAL TISSUE SCAFFOLDS AS TISSUE FILLERS - Tissue fillers derived from decellularized tissues are provided. The tissue fillers can include acellular tissue matrices that have reduced inflammatory responses when implanted in a body. Also provided are methods of making and therapeutic uses for the tissue fillers. | 2013-01-31 |
20130028985 | COMPOSITION AND METHOD FOR TREATING MIGRAINES - Disclosed are compositions for treating or preventing migraine headaches and related headaches. | 2013-01-31 |
20130028986 | Pharmaceutical Compositions - A composition comprising a pharmaceutically acceptable group (2, 4, 12, 13 or 14) metal compound for the treatment of a dermatological condition involving an abnormal decrease in the cell-to-cell adhesion between epithelial cells in the epidermal barrier. | 2013-01-31 |
20130028987 | Method of treating psoriasis - A method treating psoriasis and more specifically toward a protocol that involves the use of a specialized curcumin gel composition, the use of topical steroid cream, the avoidance of contact with allergens, and lactose-free diet and treatment of bacterial superinfection with antibiotics and bleach/chlorox baths. | 2013-01-31 |
20130028988 | COMPOSITION FOR OBESITY TREATMENT - This invention relates to a composition of a unique combination of three novel dietary supplements for use in a weight loss program. The composition includes a mood enhancer, an insulin sparing agent, and a peripheral energy blocker. Also provided is a method of treatment in a weight loss program. | 2013-01-31 |
20130028989 | MATERIALS AND METHOD FOR INHIBITING REPLICATION PROTEIN A AND USES THEREOF - Targeting uncontrolled cell proliferation and resistance to DNA damaging chemotherapeutics with at least one reagent has significant potential in cancer treatment. Replication Protein A, the eukaryotic single-strand (ss) DNA binding protein, is essential for genomic maintenance and stability via roles in both DNA replication and repair. Reported herein are small molecules that inhibits the in vitro, in vivo, and cellular ssDNA binding activity of RPA, thereby disrupting the eukaryotic cell cycle, inducing cytotoxicity and increasing the efficacy of chemotherapeutic agents damage DNA, and/or disrupt its replication and/or function. These results provide new insights into the mechanism of RPA-ssDNA interactions in chromosome maintenance and stability. This represents a molecularly targeted eukaryotic DNA binding inhibitor and demonstrates the utility of targeting a protein-DNA interaction as a means of studying the cell cycle and providing a therapeutic strategy for cancer treatment. | 2013-01-31 |
20130028990 | METHOD OF USING SOLID-LAYERED BLEACH COMPOSITIONS - The present invention provides a method of using a solid-layered composition having at least two parts. The first past comprises a) calcium hypochlorite, magnesium hypochlorite and mixtures thereof, b) a builder, c) a water-soluble polymer, d) an acid, and e) wherein the first part does not contain sodium hypochlorite, lithium hypochlorite, potassium hypochlorite and mixtures thereof. The second part comprises a) a surfactant b) a builder, c) an acid, and d) wherein the second part does not contain any oxidant. | 2013-01-31 |
20130028991 | DIETARY SUPPLEMENT FOR USE IN A WEIGHT LOSS PROGRAM - This invention relates to a dietary supplement for use in a weight loss program, which alleviates insulin resistance in the presence of the metabolic syndrome. The dietary supplement includes, in combination, berberine, banaba leaf extract, and inositol. Also provided is a method of treatment in a weight loss program. | 2013-01-31 |
20130028992 | Herbal-Based Solution for Treating Symptoms of Nasal Conditions - An herbal-based solution includes a first amount of wasabi comprising at least an allyl isothiocyanate component, and a second amount of saline solution. The saline solution and the organic material are combined to substantially dilute the wasabi in the saline solution to produce the herbal-based solution. The herbal-based solution further has anti-inflammatory, anti-microbial and anti-coagulative properties. The wasabi may include | 2013-01-31 |
20130028993 | Composition and Manufacturing Processes of a Toxicity Free Botanical Drug for Curative Treatment of Chronic Diseases - This invention discloses composition and manufacturing processes of a toxicity free botanical drug formulation for curative treatment of chronic diseases. It is manufactured from plants | 2013-01-31 |
20130028994 | POMEGRANATE EXTRACT HAVING A HIGH ELLAGIC ACID CONTENT, AND USE OF THE POMEGRANATE EXTRACT - A pomegranate pulp extract is disclosed. The pomegranate pulp extract is effective in relieving women's menopausal symptoms, anxiety disorders, depression or attention deficit disorders due to the presence of a large amount of ellagic acid. Further disclosed is a method for further improving the relieving effect of the pomegranate extract on women's menopausal symptoms, anxiety disorders, depression or attention deficit disorders. The method includes increasing the content of ellagic acid in the pomegranate extract. | 2013-01-31 |
20130028995 | NEW SYNERGISTIC COMPOSITIONS FOR THE TREATMENT OF TOPICAL VIRAL INFECTIONS - A synergistic composition comprising plant extracts rich in tannins for the treatment of topical viral infections. The plant extracts contain at least one protease inhibitor and/or at least one viral glycoprotein inhibitor. | 2013-01-31 |
20130028996 | BIOACTIVE BOTANICAL COSMETIC COMPOSITIONS AND PROCESSES FOR THEIR PRODUCTION - The present invention is directed to bioactive botanical cosmetic compositions derived from membrane and cell serum fractions of plant cell juice. The present invention also relates to the methods for preparing these bioactive botanical cosmetic compositions and the uses of these compositions in various cosmetic formulations and as topical skin cosmetic applications. | 2013-01-31 |
20130028997 | Compositions, Products, Therapeutic Uses and Procedures for the Production and/or Crystallization of Extracts of Encelia Canescens LAM (Coronilla De Fraile) - The present invention relates to a composition containing extracts of | 2013-01-31 |
20130028998 | MOLDING DIE SET AND RESIN MOLDING APPARATUS HAVING THE SAME - The molding die set includes: a first molding die having a first molding chase, a cavity piece, supported by the first molding chase, movably supported by the first molding chase and enclosing the cavity piece; a second molding die having a second molding chase, a work supporting section biased and supported by the second molding chase and on which a work will be mounted, and a center insert located adjacent to the work supporting section; and a pot being provided to one of the first molding die and the second molding die, the pot feeding resin for molding the work. The second molding die has a thickness adjusting mechanism, which makes the work supporting section absorb thickness variation of the work and brings the work into contact with the movable clamper when the work is clamped with the movable clamper of the first molding die. | 2013-01-31 |
20130028999 | PROCESS AND DEVICE FOR THE CONTINUOUS PRODUCTION OF AN EXTRUDATE FROM FINELY DIVIDED PLANT MATERIAL AND A THERMOPLASTIC MATERIAL - A device for continuous production of an extrudate from finely divided plant material and a thermoplastic material. When viewed in an extrusion direction, first the finely divided plant material and then the thermoplastic material are fed to an extrusion device, which can be a twin-screw extruder. The fed-in materials are mixed with one another, degassed and jointly extruded from the extrusion device and thus form the extrudate, and the plant material is embedded in the thermoplastic material, wherein the plant material and the thermoplastic material are fed into the extrusion device at a common position or two directly successive positions. The thermoplastic material is plastified in a separate plastifier extruder before being fed into the extrusion device and is fed from the extruder to the extrusion device in a plastified state, and the plant material is then degassed together with the thermoplastic material. | 2013-01-31 |
20130029000 | COMPRESSION MOLDING MACHINE - A compression molding machine includes a feeder that has a feeder main body, a sealing frame attached to the feeder main body and having a supply port allowing a powdery material to pass therethrough, a first elastic member comprised between the sealing frame and the feeder main body, a sealing member attached to the sealing frame and preventing the powdery material from leaking, and a second elastic member comprised between the sealing member and the sealing frame. | 2013-01-31 |
20130029001 | DEVICE FOR PRODUCING THREE-DIMENSIONAL MODELS - The present invention relates to a device for man facture of three-dimensional models by means of a 3D printing process, whereby a spreader device is used to deposit particulate material in layers on a build platform and the particulate material flow, which occurs perpendicular to the spreading direction, is transferred into containers that are actively cleaned by sliders or brushes at the spreader device. It exploits the fact that particulate material that is moves dynamically can only bridge small height differences. The arrangement can be implemented in a space-saving manner beneath the spreading plane. | 2013-01-31 |
20130029002 | Double Tread - Embodiments of the invention are used to provide ways of tire tread molding and retreading with a double tread rubber body having a unitary structure that comprises two treads in order to remove the need for buffing an oxide layer typically associated with tread molding and curing. Embodiments of the double tread molding and retreading methods also remove the need for cementing the cured tread to prevent future oxidation buildup. Once the double tread is cured and cooled, it is cut along the centerline with a double tread separation apparatus to expose a soft non-oxidized inner rubber. The cutting is much less energy intensive when compared to buffing with an expendable wire brush. There is no risk of spots of oxidized rubber being missed as is the case with buffing. There is little or no dust created. | 2013-01-31 |
20130029003 | COMPRESSION MOLDING MACHINE - A compression molding machine includes a plurality of plate units that are provided between a lower punch retainer and an upper punch retainer. The plate units each include: a plate having a through bore to be filled with a powdery material that is compressed by an upper punch and a lower punch; and a plate attachment member having a mount portion mounted to a vicinity of an upright shaft, a positioning surface positioning the upper surface of the plate, and a plate attaching portion attaching the plate from below to above, such that the upper surface of the plate is positioned at the positioning surface. | 2013-01-31 |
20130029004 | MOLDING APPARATUS - Disclosed herein is, amongst other things, a molding apparatus, comprising a stripper sleeve ( | 2013-01-31 |
20130029005 | BIRD FEED FOR ATTRACTING FINCHES AND OTHER SMALL DESIRABLE BIRDS - The invention provides various bird feed mixtures that are intrinsically attractive to desirable birds such as finches. The bird feed mixture of the invention attracts larger numbers of desirable birds than commercially available bird feed mixtures. The bird feed mixtures contain thistle, red millet and sunflower chips. | 2013-01-31 |
20130029006 | BIRD FEED FOR ATTRACTING FINCHES AND OTHER SMALL BIRDS - The invention provides a defined bird feed mixture that is intrinsically attractive to some desirable birds such as finches. The bird feed mixture of the invention attracts larger numbers of small birds than some commercially available finch bird feed mixtures. The bird feed mixture contains thistle, red millet and sunflower chips. | 2013-01-31 |
20130029007 | COCOA SENSORY CHARACTERISTICS - The present invention relates to cocoa material, such as cocoa beans and products derived therefrom, such as chocolate. The invention in particular relates to flavour characteristics of such cocoa materials. In an aspect, the invention relates to cocoa beans or a derivative thereof of a first origin having at least one sensory characteristic which is substantially equal compared to the corresponding sensory characteristic of a bulk quantity of cocoa beans or a derivative thereof of a second origin, wherein said first and said second origin are different. The present invention also relates to methods suitable for obtaining such coca beans or derivatives therefrom. | 2013-01-31 |
20130029008 | ENGINEERED COMESTIBLE MEAT - Provided are engineered meat products formed as a plurality of at least partially fused layers, wherein each layer comprises at least partially fused multicellular bodies comprising non-human myocytes and wherein the engineered meat is comestible. Also provided are multicellular bodies comprising a plurality of non-human myocytes that are adhered and/or cohered to one another; wherein the multicellular bodies are arranged adjacently on a nutrient-permeable support substrate and maintained in culture to allow the multicellular bodies to at least partially fuse to form a substantially planar layer for use in formation of engineered meat. Further described herein are methods of forming engineered meat utilizing said layers. | 2013-01-31 |
20130029009 | Apparatus for Recycling of Protein Waste and Fuel Production - Example embodiments provide an apparatus that is useful for recycling protein waste and producing fuel from protein waste. Waste is ground by a grinding means and digested by a enzyme digest medium composed of enzymes, preservatives, inedible egg and or a waste fluid that may include other protein sources with or without fat. The ground proteins are digested with the enzyme in recirculated digest tanks. Fat can be collected from the tank by addition of acid and separation of fat from water with a centrifuge. Alternatively the ground protein and enzyme can be fermented and gas collected from the digest tank in a pressure tank with a compressor. The protein solubles are emulsified, separated from water, and extruded before drying. Either fat or gas can be used to fuel a dryer. Example embodiments provide a highly digestable paletable food stuff from protein waste which is usable for pet, livestock, or an aquaculture diet. | 2013-01-31 |
20130029010 | Process For Preparing An Enzyme Containing Granule - This invention relates to a process for manufacture of a dry enzyme containing mixer granulation granule comprising the step of adding a particulate component to the mixer granulation process, wherein the particulate component constitutes less than 75 parts of the finished granule and the particles of the particulate component have an mean size of more than 40 μm in its longest dimension. Also claimed is granules of the process, granules containing more than two particles of the particulate component and composition and methods of using the granules. | 2013-01-31 |
20130029011 | PET TREAT - Provided are treats having an outer portion and an inner portion which contains a filing. The filling may include ground or diced meat and further includes additional ingredients for health benefits or palatability. The treats are highly palatable to pets and therefore very well-suited to delivery of health ingredients. | 2013-01-31 |
20130029012 | EDIBLE COATING COMPOSITION AND USES THEREOF - Described herein is an edible coating for food products in which the coatings comprises a polysaccharide cross-linked with a cross-linking agent solution. Also described herein are methods for coating food products and forming clusters of food products. The use of the edible coating for extending the shelf-life of food products is also described. | 2013-01-31 |
20130029013 | BOTTLED CARBONATED BEVERAGE CONTAINING SOYBEAN POWDER OR SOY MILK | 2013-01-31 |
20130029014 | METHOD AND APPARATUS FOR MAKING A HOLLOW BAKED PRODUCT - A hollow body is made from a flat baked wafer cake by first juxtaposing the wafer cake with a cavity of a deep-drawing mold and then forming edge regions of the cake with a plurality of deformations out of a plane of the cake at a uniformly spacing around a periphery of the cake. Then the cake is pushed by a deep-drawing punch into the cavity to it into a hollow body and to form each of the deformations into a multilayer fold. | 2013-01-31 |
20130029015 | FOOD COMPOSITION OF VEGETABLES FOR DEVELOPING NATURAL FOODS SUCH AS: SAUSAGES, HAMBURGERS - Food composition for making sausages or hamburgers comprising a vegetable, selected from among Swiss chard, spinach, mushroom, sweetcom or another, a proteinaceous material, salt and water and, optionally, antioxidants and flavourings, both thereof in particular of natural origin. The proteinaceous material used comprises a combination of proteins isolated from soya and proteins isolated from whey. The method of preparation of the composition comprises mixing the proteinaceous material with water, adding ice in flakes and forming an emulsion, to which are added the vegetable and the salt and, in an optional manner, antioxidants and/or flavourings. | 2013-01-31 |
20130029016 | BEVERAGE CARBONATOR AND METHOD FOR PRODUCING SUCH CARBONATED BEVERAGE - The invention provides a beverage carbonator ( | 2013-01-31 |
20130029017 | COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF METABOLIC DISEASES - The present invention is a new method and composition that enhance bone repair, formation, maintenance and slowing of bone resorption. The present invention relates to methods and compositions that enhance collagen formation, tendon health and tendon injury healing, bone maintenance and bone injury healing, and the prevention and treatment of metabolic diseases. The present invention is a part of the therapy to maintain bone health among patients with diabetic bone resorption and others with metabolic disorders. In one embodiment, the composition is a composite of hydroxyapatite and an organic matrix composed of milk pH-dependent serum proteins, i.e., bone morphogenic proteins (BMP), milk serum-derived specific proteins (MSSP), and milk serum derived proteins. | 2013-01-31 |